Advertisement

Topics

Ritter Pharmaceuticals Reports Further Analysis from its Phase 2b/3 Trial Results Demonstrating Significant Reductions in Lactose Intolerance Symptoms / Analysis shows clinically meaningful benefit from symptoms, global patient-reported and real-world as

09:31 EDT 3 Aug 2017 | FinanzNachrichten

LOS ANGELES, CA -- (Marketwired) -- 08/03/17 -- Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (the "Company"), a developer of novel therapeutic products that modulate the human gut microbiome to tre...

Original Article: Ritter Pharmaceuticals Reports Further Analysis from its Phase 2b/3 Trial Results Demonstrating Significant Reductions in Lactose Intolerance Symptoms / Analysis shows clinically meaningful benefit from symptoms, global patient-reported and real-world as

NEXT ARTICLE

More From BioPortfolio on "Ritter Pharmaceuticals Reports Further Analysis from its Phase 2b/3 Trial Results Demonstrating Significant Reductions in Lactose Intolerance Symptoms / Analysis shows clinically meaningful benefit from symptoms, global patient-reported and real-world as"

Quick Search
Advertisement